|
Orthologous residues
|
|
PEA‑15 (human): S116‑p, PEA‑15 (mouse): S116‑p, PEA‑15 (rat): S116‑p, PEA‑15 (hamster): S116‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
brain cancer, glioma, breast cancer
|
|
Relevant cell lines - cell types - tissues:
CHO (fibroblast), mammary gland, MDA-MB231 (breast cell)
|
|
Cellular systems studied:
cell lines, tissue
|
|
Species studied:
hamster, human
|
|
Comments:
Glioma CRL-1620 cells
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Effect of modification (process):
cell cycle regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
ERK1 (human)
|
|
Disrupts
|
|
|
pull-down assay
|
|
ERK2 (human)
|
|
Disrupts
|
intracellular localization
|
cell adhesion, altered, transcription, altered
|
co-immunoprecipitation, pull-down assay
|
|